As decreased adiponectin, a molecule which antagonizes hepatic lipid accumulation and has insulin-sensitizing, anti-inflammatory, and anti-fibrotic effects [8] plays a pivotal role in NAFLD pathogenesis [9-11,13], and the I148M PNPLA3 polymorphism involved in the regulation of lipid metabolism predisposes to the progression of liver diseases associated with steatosis by still undefined mechanisms, we evaluated whether PNPLA3 genotype influenced adiponectin levels. Here, ADIPOQ is linked to liver disorder.